J. Moake, Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies, Best Practice & Research Clinical Haematology, vol.22, issue.4, p.56776, 2009.
DOI : 10.1016/j.beha.2009.07.004

G. Levy, W. Nichols, E. Lian, T. Foroud, J. Mcclintick et al., Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura, Nature, vol.228, issue.6855, p.48894, 2001.
DOI : 10.1038/35097008

H. Tsai and E. Lian, Antibodies to von Willebrand Factor???Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.339, issue.22, p.158594, 1998.
DOI : 10.1056/NEJM199811263392203

E. Mariotte, E. Azoulay, L. Galicier, E. Rondeau, F. Zouiti et al., Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy, The Lancet Haematology, vol.3, issue.5, p.23745, 2016.
DOI : 10.1016/S2352-3026(16)30018-7

E. Moschcowitz, An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease, Am J Med. nov, vol.13, issue.5, p.5679, 1952.

M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P. Kyrle et al., von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family Partial amino acid sequence of purified von Willebrand factor-cleaving protease, Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura, pp.14325-11165461, 1982.

J. Jimenez, W. Jy, L. Mauro, L. Horstman, and Y. Ahn, Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease, British Journal of Haematology, vol.260, issue.1, p.8190, 2001.
DOI : 10.1016/S0049-3848(98)00151-0

W. Jy, J. Jimenez, L. Mauro, L. Horstman, P. Cheng et al., Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13- deficient mice, J Thromb Haemost JTH. juin J Clin Invest. oct, vol.3115, issue.6, p.275261, 2005.

F. Anderson, H. Wheeler, R. Goldberg, D. Hosmer, N. Patwardhan et al., A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study, Archives of Internal Medicine, vol.151, issue.5, p.9338, 1991.
DOI : 10.1001/archinte.151.5.933

J. Huang, D. Motto, D. Bundle, J. F. Sadler, K. Kokame et al., Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13- deficient mice Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 15 avr):31616. 21. Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome? Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center, ):1006. 24. Morgand M, pp.36539245760-2238997, 2004.

S. Massberg, L. Grahl, V. Bruehl, M. Manukyan, D. Pfeiler et al., Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases, Nature Medicine, vol.209, issue.8, p.88796, 2010.
DOI : 10.1038/nm.2184

M. Demers and D. Wagner, Neutrophil extracellular traps promote deep vein thrombosis in mice):13644. 29 Neutrophil extracellular traps: A new link to cancerassociated thrombosis and potential implications for tumor progression, J Thromb Haemost JTH. janv Oncoimmunology. 1 févr, vol.102, issue.12, p.22946, 2012.

C. Loirat, J. Girma, C. Desconclois, P. Coppo, and A. Veyradier, Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children, Pediatric Nephrology, vol.8, issue.Suppl, p.1929, 2009.
DOI : 10.1007/s00467-008-0863-5

J. Studt, K. Hovinga, J. Radonic, R. Gasparovic, V. Ivanovic et al., Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins, Blood, vol.103, issue.11, p.41957, 2004.
DOI : 10.1182/blood-2003-11-3888

M. Scully, J. Brown, R. Patel, V. Mcdonald, C. Brown et al., severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link Recent advances in thrombotic thrombocytopenic purpura, DRB1*11: a strong risk factor for acquired F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura, pp.8569-3425762, 2004.

P. Mannucci, M. Canciani, I. Forza, F. Lussana, A. Lattuada et al., Changes in health and disease of the metalloprotease that cleaves von Willebrand factor, Blood, vol.98, issue.9, p.27305, 2001.
DOI : 10.1182/blood.V98.9.2730

M. Roriz, M. Landais, J. Desprez, C. Barbet, E. Azoulay et al., Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange, Medicine (Baltimore). oct Transfusion (Paris). août, vol.9450115, issue.1662, pp.1598-39165464150011, 2010.

T. Raife, B. Atkinson, R. Montgomery, S. Vesely, K. Friedman et al., Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion (Paris) Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review, févr Eur J Haematol. oct, vol.4481, issue.24, pp.14650-423116, 2004.

K. Gandhi, W. Aronow, H. Desai, H. Amin, M. Sharma et al., Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13 Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review, Clin Cardiol. avr J Thromb Haemost JTH. févr J Thromb Haemost JTH. avr Hawkins BM Transfusion févr, vol.3313748, issue.4242, pp.2136-44293302, 2008.

D. Patschan, O. Witzke, U. Dührsen, R. Erbel, T. Philipp et al., Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc Thrombotic thrombocytopenic purpura and its diagnosis, juin J Thromb Haemost JTH. nov, vol.213, issue.611, pp.24207-24256, 2005.

S. Ferrari, F. Scheiflinger, M. Rieger, G. Mudde, M. Wolf et al., Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 1 avr Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases, ):281522. 52. Coppo P, pp.176572-543937, 1991.

S. Allford, B. Hunt, P. Rose, S. Machin, H. Braine et al., Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients, Br J Haematol. févr N Engl J Med. 8 août, vol.120325, issue.46, p.398403, 1991.

R. Bukowski, J. Hewlett, R. Reimer, C. Groppe, J. Weick et al., Therapy of Thrombotic Thrombocytopenic Purpura: An Overview, ):18. 58. del Zoppo GJ. Antiplatelet therapy in thrombotic thrombocytopenic purpura, p.1309, 1981.
DOI : 10.1055/s-2007-1005062

M. Rosove, W. Ho, and D. Goldfinger, Ineffectiveness of Aspirin and Dipyridamole in the Treatment of Thrombotic Thrombocytopenic Purpura, Annals of Internal Medicine, vol.96, issue.1, pp.2733-60, 1982.
DOI : 10.7326/0003-4819-96-1-27

C. Bennett, P. Weinberg, K. Rozenberg-ben-dror, P. Yarnold, H. Kwaan et al., Results of a randomized multicenter trial by the Italian Cooperative Group for TTP, Antiplatelet agents in thrombotic thrombocytopenic purpura, pp.42935-61, 1997.

Y. Page, B. Tardy, F. Zeni, C. Comtet, R. Terrana et al., Thrombotic thrombocytopenic purpura related to ticlopidine, The Lancet, vol.337, issue.8744, pp.5414-627746, 1991.
DOI : 10.1016/0140-6736(91)91383-6

P. Ruggenenti, G. Remuzzi, D. Harkness, J. Byrnes, E. Lian et al., Pathophysiology and management of thrombotic microangiopathies Hazard of platelet transfusion in thrombotic thrombocytopenic purpura, J Nephrol. déc JAMA. 23 oct, vol.11246, issue.6417, p.3001019313, 1981.

L. Gordon, H. Kwaan, E. Rossi, J. De-la-rubia, G. Plumé et al., Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy Platelet transfusion and thrombotic thrombocytopenic purpura, Semin Hematol. juill Transfusion, vol.2442, issue.6610, p.13845, 1987.

S. Tripathi, A. Deshpande, S. Khadse, R. Kulkarni, P. Coppo et al., Case of TTP with cerebral infarct secondary to platelet transfusion):10911. 68 Effectiveness of platelet transfusions after plasma exchange in adult thrombotic thrombocytopenic purpura: a report of two cases, Indian J Pediatr. janv Am J Hematol. nov, vol.7868, issue.13, 2001.

Y. Benhamou, J. Baudel, A. Wynckel, L. Galicier, E. Azoulay et al., Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura, pp.10411-7234957, 1989.

L. Gutterman and T. Stevenson, Treatment of thrombotic thrombocytopenic purpura with vincristine, JAMA. 12 mars, vol.247, issue.10, p.14336, 1982.

J. Welborn, P. Emrick, M. Acevedo, F. Ferrara, M. Annunziata et al., Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura?, Am J Hematol. sept Ann Hematol. janv Can J Surg J Can Chir. oct, vol.358153, issue.115, pp.1821-77710, 1990.

J. Chemnitz, A. Draube, C. Scheid, P. Staib, A. Schulz et al., Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab, American Journal of Hematology, vol.68, issue.20, p.1058, 2002.
DOI : 10.1002/ajh.10204

L. Gutterman, B. Kloster, H. Tsai, A. Pallera, L. Goodnough et al., Rituximab Therapy for Refractory Thrombotic Thrombocytopenic Purpura, Blood Cells, Molecules, and Diseases, vol.28, issue.3, 2002.
DOI : 10.1006/bcmd.2002.0522

M. Scully, H. Cohen, J. Cavenagh, S. Benjamin, R. Starke et al., Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13, British Journal of Haematology, vol.138, issue.3, p.45161, 2007.
DOI : 10.1111/j.1365-2141.2004.04836.x

N. Tun and G. Villani, Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis, Journal of Thrombosis and Thrombolysis, vol.23, issue.2, p.34759, 2012.
DOI : 10.1007/s11239-012-0723-9

H. Kierdorf, N. Maurin, B. Heintz, W. Bachman, and J. Brennan, Cyclosporine for thrombotic thrombocytopenic purpura Refractory thrombotic thrombocytopenic purpura treated with cyclosporine, Ann Intern Med. 15 juin Am J Hematol. janv, vol.11851, issue.881, p.9878934, 1993.

D. Pasquale, R. Vidhya, K. Dasilva, M. Tsan, L. Lansing et al., Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine, Am J Hematol. janv, vol.57, issue.1, p.5761, 1998.

K. Jhaveri, A. Scheuer, J. Cohen, G. B. Cataland, S. et al., Treatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporine):1922. 91 Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity Cyclosporineassociated thrombotic microangiopathy in renal allografts, ):48693. 92. Zarifian A, p.245766, 1999.

J. Shortt, D. Oh, S. Opat, T. Van-balen, M. Schreuder et al., Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report, ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura, pp.902-94802, 2013.

J. Chen, A. Reheman, F. Gushiken, L. Nolasco, X. Fu et al., Nacetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice, J Clin Invest. févr, vol.121, issue.2, p.593603, 2011.

G. Li, S. Rambally, J. Kamboj, S. Reilly, J. Moake et al., Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report, Transfusion, vol.54, issue.5, p.12214, 2014.

A. Rottenstreich, S. Hochberg-klein, D. Rund, and Y. Kalish, The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura, Journal of Thrombosis and Thrombolysis, vol.54, issue.25, p.67883, 2016.
DOI : 10.1007/s11239-015-1259-6

F. Peyvandi, M. Scully, K. Hovinga, J. Cataland, S. Knöbl et al., Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.374, issue.6, p.51122, 2016.
DOI : 10.1056/NEJMoa1505533

B. Plaimauer and F. Scheiflinger, Expression and characterization of recombinant human ADAMTS-13, Seminars in Hematology, vol.41, issue.1, p.2433, 2004.
DOI : 10.1053/j.seminhematol.2003.10.006

G. Antoine, K. Zimmermann, B. Plaimauer, M. Grillowitzer, J. Studt et al., ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13, British Journal of Haematology, vol.87, issue.5, p.8214, 2003.
DOI : 10.1074/jbc.C100515200

A. Schiviz, K. Wuersch, C. Piskernik, B. Dietrich, W. Hoellriegl et al., A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13, Blood, vol.119, issue.25, p.612835, 2012.
DOI : 10.1182/blood-2011-09-380535

B. Plaimauer, K. Hovinga, J. Juno, C. Wolfsegger, M. Skalicky et al., Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies, Journal of Thrombosis and Haemostasis, vol.95, issue.5, p.93644, 2011.
DOI : 10.1111/j.1538-7836.2011.04224.x

C. Jian, X. J. Gong, L. Skipwith, C. Jin, S. Kwaan et al., Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood, p.383643, 2012.

K. Hovinga, J. Vesely, S. Terrell, D. Lämmle, B. George et al., Survival and relapse in patients with thrombotic thrombocytopenic purpura, Blood, vol.115, issue.8, p.150011, 2010.
DOI : 10.1182/blood-2009-09-243790

J. Patton, K. Manning, D. Case, and J. Owen, Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura, American Journal of Hematology, vol.18, issue.2, p.949, 1994.
DOI : 10.1002/ajh.2830470206

F. Peyvandi, S. Lavoretano, R. Palla, H. Feys, K. Vanhoorelbeke et al., ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission, Haematologica, vol.93, issue.2, p.2329, 2008.
DOI : 10.3324/haematol.11739

G. Moulis, A. Palmaro, J. Montastruc, B. Godeau, M. Lapeyre-mestre et al., Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, vol.124, issue.22, p.330815, 2014.
DOI : 10.1182/blood-2014-05-578336

E. Burns, Y. Lou, and A. Pathak, Morphologic diagnosis of thrombotic thrombocytopenic purpura, American Journal of Hematology, vol.28, issue.1, p.1821, 2004.
DOI : 10.1002/ajh.10450

A. Sarpatwari, D. Bennett, J. Logie, A. Shukla, K. Beach et al., Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database, Haematologica, vol.95, issue.7, p.116775, 2010.
DOI : 10.3324/haematol.2009.018390

D. Arnold, Bleeding complications in immune thrombocytopenia. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program, p.23742, 2015.

R. Centurioni, E. Bobbio-pallavicini, C. Porta, F. Rodeghiero, L. Gugliotta et al., Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP, Haematologica. août, vol.80, issue.4, p.32531, 1995.